Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Read full text
Authors: Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, R Fenk, Katja Weisel, Lilli Podola, Uta Bertsch, Alexander Brobeil, Julia Mersi, Stefanie Huhn, Ryan Arlinghaus
+21 more Michael Hundemer, Stephan R. Bohl, K. Elias, Natalie Schub, Johannes M. Waldschmidt, Florian Bassermann, Carsten Müller‐Tidow, Christoph Heuck, Caline Sakabedoyan, Josephine Khan, Elena Ershova, Bas D. Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, on behalf of the GMMG-HD10/DSMM-XX (MajesTEC-5) investigators, K. Martin Kortüm
Cited by: 4
References: 33

Abstract

Abstract Advancements in frontline therapies have substantially improved outcomes in newly diagnosed multiple myeloma (NDMM); however, many patients will not achieve deep responses and will relapse. Teclistamab, a BCMA×CD3 bispecific antibody, in combination with daratumumab, has demonstrated strong efficacy in relapsed/refractory multiple myeloma versus standard of care as early as first relapse. This ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) study evaluates teclistamab-based regimens in transplant-eligible NDMM. In this prespecified pooled analysis of three cohorts, 49 patients received teclistamab/daratumumab/lenalidomide (Tec-DR; arms A and A1) or Tec-DR with bortezomib (Tec-DVR; arm B). Primary endpoints were incidence and severity of adverse events (AEs) and serious AEs; secondary endpoints included overall response rate (ORR), minimal residual disease (MRD) negativity and MRD-negative complete response (CR). The current analysis spans the induction and autologous stem cell transplantation phases until the premaintenance timepoint. Grade 3 or 4 treatment-emergent AEs (TEAEs) occurred in 91.8% (45/49); most were hematologic (lymphopenia (59.2%; 29/49), neutropenia (59.2%; 29/49) and leukopenia (18.4%; 9/49)). No grade 5 TEAEs were reported. Serious AEs occurred in 55.1% (27/49); pyrexia (12.2% (6/49)) was most common. Any-grade and grade 3 or 4 infections occurred in 81.6% (40/49) and 36.7% (18/49), respectively, the most common grade 3 or 4 infections being COVID-19 and pneumonia (6.1% (3/49) each). Cytokine release syndrome occurred in 67.3% (33/49); all were grade 1 or 2, all resolved and none led to discontinuation of any study treatment. No treatment-related immune effector cell-associated neurotoxicity syndrome (ICANS) events occurred. Across arms, the MRD-negative CR rate was 91.8% (45/49) by the premaintenance timepoint; the MRD negativity rate was 100% in evaluable samples at postinduction cycle 3 (1 × 10 −5 (46/46)), cycle 6 (1 × 10 −5 (46/46) and 1 × 10 −6 (46/46)) and premaintenance (1 × 10 −5 (40/40)); the ORR was 100% (49/49). Total median stem cell yield was 8.1 × 10 6 per kg. Data support the feasibility of Tec-D(V)R induction in transplant-eligible NDMM, with a consistent safety profile compared with individual regimen components and notable early MRD negativity rates. ClinicalTrials.gov identifier: NCT05695508 .

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Radiopharmaceutical Chemistry and Applications Protein Degradation and Inhibitors

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
7
Pages
2440–2448
Publication date
25 June 2026
Language
EN